Scinai Immunotherapeutics
SCNI
4 hedge funds and large institutions have $45.2K invested in Scinai Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
47% less capital invested
Capital invested by funds: $85.1K → $45.2K (-$39.9K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$29.3K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$295 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $40.2K | -$29.3K | -8,556 | -36% |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $4.17K | -$295 | -86 | -5% |
|
3
Morgan Stanley
New York
| $687 | – | – | – |
|
4
Credit Agricole
Montrouge Cedex,
France
| $113 | – | – | – |
|
SCNI Hedge Fund Activity: Q1 2025 in Review
4 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2025, worth a combined $45.2K — down 47% from $85.1K a quarter earlier.
Fund positioning in SCNI was balanced in Q1 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was UBS Group, cutting an estimated $29.3K.
- 4 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $45.2K of Scinai Immunotherapeutics stock for Q1 2025, down 47% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q1 2025 and 0 closed out.
- The largest Scinai Immunotherapeutics seller in Q1 2025 was UBS Group, an estimated $29.3K sold.
Based on aggregated 13F filings for Q1 2025.